About Celgene
Celgene is a company based in Summit (United States) founded in 1986 was acquired by Bristol-Myers Squibb in January 2019.. Celgene has raised $45 million across 6 funding rounds from investors including Mesoblast, Bristol-Myers Squibb and Geneva Partners. The company has 4,891 employees as of December 31, 2020. Celgene has completed 11 acquisitions, including Abraxis BioScience, Acetylon and Avila Therapeutics. Celgene operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Summit, United States
- Employees 4891 as on 31 Dec, 2020
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Celgene
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$45 M (USD)
in 6 rounds
-
Latest Funding Round
$4.1 M (USD), Post-IPO
Feb 10, 2018
-
Investors
Mesoblast
& 3 more
-
Employee Count
4891
as on Dec 31, 2020
-
Investments & Acquisitions
Abraxis BioScience
& 10 more
-
Acquired by
Bristol-Myers Squibb
(Jan 03, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
394 people
Software Development Team
340 people
Senior Team
99 people
Product Management Team
97 people
Operations Team
83 people
Data Analysis and Operations Team
60 people
Sales and Marketing
58 people
Human Resources and Administration
45 people
Unlock access to complete
Funding Insights of Celgene
Celgene has successfully raised a total of $45M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $4.1 million completed in February 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 6
- Last Round Post-IPO — $4.1M
-
First Round
First Round
(26 Oct 2008)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2018 | Amount | Post-IPO - Celgene | Valuation |
investors |
|
| Nov, 2017 | Amount | Debt – Conventional - Celgene | Valuation |
investors |
|
| Apr, 2015 | Amount | Private Equity Round - Celgene | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Celgene
Celgene has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Mesoblast, Bristol-Myers Squibb and Geneva Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Offers comprehensive investment advisory and financial planning services to clients.
|
Founded Year | Domain | Location | |
|
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
Founded Year | Domain | Location | |
|
Administers health care and support for military personnel and operations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Celgene
Celgene has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include Abraxis BioScience, Acetylon and Avila Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Regulatory T cell therapeutics for autoimmune diseases are developed.
|
2015 | ||||
|
T-cell bispecific antibodies are developed for cancer treatment.
|
2013 | ||||
|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
2013 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Celgene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Celgene Comparisons
Competitors of Celgene
Celgene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| domain | founded_year | HQ Location |
Outsourced contract research organization services are provided to clients.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Celgene
Frequently Asked Questions about Celgene
When was Celgene founded?
Celgene was founded in 1986 and raised its 1st funding round 22 years after it was founded.
Where is Celgene located?
Celgene is headquartered in Summit, United States.
Who is the current CEO of Celgene?
Sol J. Bare is the current CEO of Celgene.
Is Celgene a funded company?
Celgene is a funded company, having raised a total of $45M across 6 funding rounds to date. The company's 1st funding round was a Private Equity Round of $45M, raised on Oct 26, 2008.
How many employees does Celgene have?
As of Dec 31, 2020, the latest employee count at Celgene is 4,891.
What does Celgene do?
Celgene is developing therapies for multiple myeloma, inflammatory diseases, and various forms of cancer. The companys lead molecule BCMA CAR T is used for treating multiple myeloma. The candidate is in phase II clinical study. Other candidates are in phase I and II, used for treating various cancers. In 2018, the company recorded annual revenues of 15.28B, and a net profit of 4.04B.
Who are the top competitors of Celgene?
Celgene's top competitors include Juno Therapeutics, Lyell Immunopharma and Autolus.
How many acquisitions has Celgene made?
Celgene has made 11 acquisitions, including Abraxis BioScience, Acetylon, and Avila Therapeutics.
Who are Celgene's investors?
Celgene has 4 investors. Key investors include Mesoblast, Bristol-Myers Squibb, Geneva Partners, and Military Health.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.